Lakefront Biotherapeutics (LKFT) Enterprise Value (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Enterprise Value for 13 consecutive years, with -$3.4 billion the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 54.02% year-over-year to -$3.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 billion (up 54.02% YoY) and the FY2025 annual result came in at -$3.5 billion, up 53.5% from the prior year.
• Enterprise Value advanced to -$3.4 billion in Q1 2026 per LKFT's latest filing, from -$3.4 billion in the prior quarter.
• Over the last five years, Enterprise Value for LKFT reached as high as $2.9 billion in Q3 2022 and fell as low as -$8.0 billion in Q1 2024.
• A 5-year average of -$4.1 billion and a median of -$4.2 billion in 2023 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2022 — Enterprise Value surged 61.71% — and 2025, when it slumped 14552.36%.
• Year by year, Enterprise Value stood at -$2.0 billion in 2022, then sank by 104.62% to -$4.2 billion in 2023, then grew by 15.39% to -$3.5 billion in 2024, then grew by 3.83% to -$3.4 billion in 2025, then gained by 0.53% to -$3.4 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$3.4 billion, -$3.4 billion, and -$7.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.